Collagen Matrix Sustained Release Anesthetic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing post-surgical pain, such as wound infiltration with local anesthetics, are inconsistent and lack strong evidence for effectiveness, leading to variable results and potential systemic toxicity from anesthetics like bupivacaine.
Innovation Solution
A drug delivery device comprising a fibrillar collagen matrix impregnated with amino amide or amino ester anesthetics, such as bupivacaine, which provides sustained release of the anesthetic at the surgical site, reducing the need for systemic analgesia and minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If wound infiltration with local anesthetic is used, then postoperative pain relief is achieved, but the duration of analgesia is insufficient and requires repeated dosing
Solution Approach 1:
The anesthetic drug is pre-loaded into the collagen matrix before surgery, enabling sustained release over an extended period without requiring repeated intraoperative or postoperative dosing interventions
Solution Approach 2:
The collagen matrix provides continuous release of the anesthetic drug at the surgical site, maintaining therapeutic levels over 48-72 hours rather than requiring intermittent re-administration
2Reliability
If high doses of systemic analgesics are administered, then adequate pain control is achieved, but systemic toxicity and adverse effects increase
Solution Approach 1:
The anesthetic is delivered locally at the surgical site through the collagen matrix, creating high local concentration for effective pain control while minimizing systemic absorption and associated toxicity
Solution Approach 2:
The collagen matrix acts as a localized reservoir and delivery vehicle, mediating between the anesthetic drug and the surgical site to achieve therapeutic effect without requiring high systemic doses
3Ease of operation
If conventional wound infiltration is used, then procedural simplicity is maintained, but consistency of pain relief is poor
Solution Approach 1:
The anesthetic is pre-loaded into the collagen matrix during manufacturing, ensuring consistent drug delivery without requiring precise intraoperative dosing techniques
Solution Approach 2:
The collagen matrix controls the release kinetics of the anesthetic, transforming the delivery parameters from rapid washout to sustained release over 48-72 hours, thereby improving consistency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device offers prolonged local analgesia lasting up to 48-72 hours, significantly reducing morphine consumption and associated adverse effects, while maintaining safety by minimizing systemic anesthetic levels.
Implementation Method 1
The at least one drug substance being substantially homogeneously dispersed in the collagen matrix
Data Source
AI summary
The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.